Lundbeck to develop therapeutic antibodies for CNS

In a groundbreaking agreement, H. Lundbeck A/S has entered into a collaboration with Genmab A/S to develop human antibody therapeutics for disorders of the central nervous system. This will be Lundbeck’s first entry into antibody therapeutics.